

**Please cite the Published Version**

Fawole, HO, Idowu, OA, Abaraogu, UO, Dell'isola, A, Riskowski, JL, Oke, KI, Adeniyi, AF, Mbada, CE, Steultjens, MP and Chastin, SFM (2021) Factors associated with fatigue in hip and/or knee osteoarthritis: A systematic review and best evidence synthesis. *Rheumatology Advances in Practice*, 5 (1). rkab013-rkab013. ISSN 2514-1775

**DOI:** <https://doi.org/10.1093/rap/rkab013>

**Publisher:** Oxford University Press

**Version:** Published Version

**Downloaded from:** <https://e-space.mmu.ac.uk/630922/>

**Usage rights:**  [Creative Commons: Attribution-Noncommercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/)


**Additional Information:** This is an Open Access article published in *Rheumatology Advances in Practice* by Oxford University Press.

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

## Systematic review meta-analysis

# Factors associated with fatigue in hip and/or knee osteoarthritis: a systematic review and best evidence synthesis

Henrietta O. Fawole <sup>1,2</sup>, Opeyemi A. Idowu<sup>2</sup>, Ukachukwu O. Abaraogu<sup>1,3</sup>, Andrea Dell'Isola<sup>4</sup>, Jody L. Riskowski<sup>1</sup>, Kayode I. Oke<sup>2</sup>, Ade F. Adeniyi<sup>5</sup>, Chidozie E. Mbada<sup>6</sup>, Martijn P. Steultjens<sup>1</sup> and Sebastien F. M. Chastin<sup>1,7</sup>

### Abstract

**Objective** The aim was systematically to identify and evaluate factors related to fatigue in individuals with hip and/or knee OA.

**Methods** A systematic literature search was conducted using AMED, CINAHL, MEDLINE, ProQuest and Web of Science Core Collections databases. Inclusion criteria comprised cross-sectional, case-control or longitudinal studies on patients with a diagnosis of hip and/or knee OA that included self-reported fatigue measures. Study quality was assessed using the National Heart, Lung and Blood Institute quality appraisal tool, and factors were synthesized within a bio-behavioural framework. Study designs and quality were combined to determine current evidence levels using best evidence synthesis grading. The full review protocol is available from PROSPERO (PROSPERO 2019: CRD42019138571).

**Results** Twenty-four studies were included, of which 19 were high, 4 moderate and 1 low quality. There was strong evidence of an association between poor self-reported physical function and high depressive symptoms with higher fatigue. Moderate evidence of an association was found between severe pain, high numbers of co-morbidities and low physical activity levels with higher fatigue. There was moderate or limited evidence of no association between most sociodemographic factors and radiographic OA severity with fatigue.

**Conclusion** Targets for fatigue management might include improving physical function, reducing depressive symptoms, pain and co-morbidities, and increasing physical activity levels. There is a need for more rigorous longitudinal studies to understand the causal effect of fatigue determinants within the hip and knee OA populations.

**Key words:** osteoarthritis, fatigue, factors, correlates, predictors, systematic review

### Key messages

- Physical function, depression, co-morbidities, pain and physical inactivity are associated with fatigue based on strong to moderate best evidence.
- Sociodemographics, body mass index and radiographic OA severity are not associated with fatigue based on limited to moderate best evidence.
- To manage fatigue, physical function, depressive symptoms, pain, co-morbidities and physical activity could be targeted.

<sup>1</sup>Centre for Living, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK, <sup>2</sup>Department of Physiotherapy, College of Medical Sciences, University of Benin, Benin-city, <sup>3</sup>Department of Medical Rehabilitation, University of Nigeria, Enugu, Nigeria, <sup>4</sup>Department of Clinical Sciences, Orthopaedics, Clinical Epidemiology Unit, Faculty of Medicine, Lund University, Lund, Sweden, <sup>5</sup>Department of Physiotherapy, University of Ibadan, Oyo State, <sup>6</sup>Department of Medical Rehabilitation,

Obafemi Awolowo University, Osun State, Nigeria and <sup>7</sup>Department of Movement and Sports Science, Ghent University, Ghent, Belgium  
Submitted 22 October 2020; accepted 22 January 2021

Correspondence to: Henrietta O. Fawole, Department of Physiotherapy, College of Medical Sciences, University of Benin, PMB 1154, Edo State, Nigeria.  
E-mail: henrietta.fawole@uniben.edu; fawolehenrieta@yahoo.com

## Introduction

OA is the most common form of arthritis and accounts for >80% of global arthritis burden [1]. The recent surge in the obesity epidemic and the increase in the global ageing population have contributed to the higher global prevalence of OA [1]. Hip and knee OA is expected to become the ninth leading cause of years lived with disability by 2030 [2] and, consequently, continue to be a major cause of reduced quality of life for those afflicted [3]. Pain is the cardinal symptom of OA and a significant contributor to functional limitations and reduction in physical activity among individuals with OA [4]. Fatigue, however, has recently emerged as an important and prevalent symptom impacting the lives of individuals with OA [5, 6].

Fatigue is generally defined as an unpleasant and subjective feeling of tiredness, exhaustion or lack of energy [7]. Moreover, aside from pain, fatigue is a common symptom and a significant concern for people with OA [8–10]. Fatigue in OA has been identified as a research priority [11] and recommended in rheumatic diseases, including OA, to be considered as a top priority in clinical practice [12]. Between 47 and 90% of those with OA report some levels of fatigue [5, 13, 14], with >40% reporting clinically significant fatigue levels [5, 13]. These levels are higher than those reported for the general population, where fatigue prevalence ranged between 13 and 25% [15–17]. Equally, fatigue levels were found to be higher for those with OA relative to their age- and sex-matched counterparts [18, 19].

With increasing interest in fatigue, the evidence on OA-related symptoms, behaviours and socioeconomic factors that contribute to fatigue preponderance has not been established within the hip and/or knee OA population, the largest population of those with OA. Evaluating the evidence on correlates or predictors for fatigue in hip and/or knee OA can help in identifying treatment plans or interventions for management or reduction of fatigue within these populations, thereby maximizing overall patient outcomes and quality of life. In order to increase the knowledge on fatigue aetiology in individuals with hip or knee OA and to design appropriate targeted fatigue interventions, the use of a conceptual framework might be beneficial in the identification of potential multifactorial correlates of fatigue. Therefore, the overarching aim of this systematic review was to identify and give an overview of predictors or correlates of fatigue in hip and/or knee OA populations using the bio-behavioural conceptual framework [20, 21]. The bio-behavioural conceptual framework was used in this systematic review because it is likely that the aetiology of fatigue is through biological or behavioural contributions [22]. Moreover, the aim of the bio-behavioural model of symptom management is within the context of a health experience that is based on interactions between biological, behavioural and social factors and their effects to explain symptoms or symptom clusters that subsequently affect health outcomes, such as fatigue [22, 23].

## Methods

### Review

This review was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline [24]; see [Supplementary Data S1](#), available at *Rheumatology Advances in Practice* online. A review protocol was registered with the PROSPERO database in July 2019 (number CRD42019138571).

### Search strategy and article selection

Electronic databases were searched from inception to 18 March 2020: AMED and CINAHL (via EBSCOhost); MEDLINE, ProQuest (Health and Medical Collections, Nursing and Allied Health database, PsycINFO) and Web of Science core collection. The search strategy was formulated in Medline and was reviewed using the PRESS guideline assessment form [25] by a researcher experienced in systematic review methodology. Search strings were translated and adapted for each database search engine. The following keywords, medical headings in combinations with specific database search syntax, filters, limiters and Boolean operators were used: ‘fatigue’ OR ‘vitality’ OR ‘tiredness’ AND ‘factors’ OR ‘correlates’ OR ‘predictors’ OR ‘determinants’ OR ‘risk factors’ OR ‘depression’ OR ‘sleep’ OR ‘pain’ AND ‘osteoarthritis’ OR ‘knee osteoarthritis’ OR ‘hip osteoarthritis’. The complete strategy implemented is presented in [Supplementary Table S1](#), available at *Rheumatology Advances in Practice* online. Reference lists of selected studies were searched to identify relevant studies, and citations (using Google Scholar) of all eligible articles and narrative reviews references were checked for further eligible texts.

### Study selection criteria

#### *Inclusion and exclusion criteria*

Peer-reviewed studies that included a hip and/or knee OA population or sub-sample of hip and/or knee OA diagnosed using radiographic evidence and/or clinical diagnosis (as defined by the American College of Rheumatology criteria) [26] or according to Kellgren–Lawrence (KL) grading [27] or doctor/physician-confirmed diagnosis and that measured fatigue as an outcome or as a predictor or used subscale questionnaires for fatigue measurement (e.g. SF-36 vitality scale) were eligible for inclusion. The following study designs were included: observational studies (cohort, case-control and cross-sectional). Articles that included participants with hip and/or knee joint replacement, review articles or grey literature or abstracts or non-human and non-English studies were excluded.

### Study selection

Studies identified by the search were screened independently based on titles and abstracts by two authors

(H.O.F. and O.A.I.). The eligible full texts were screened further by H.O.F. and O.A.I. In cases of disagreement, both authors discussed and reached a consensus. Where consensus could not be reached, a third author (U.O.A.) was consulted for the final decision.

### Data extraction

Two authors (H.O.F. and O.A.I.) extracted the following information independently from all included studies using a pre-piloted data extraction form: study setting, study population, study design, sample size, fatigue measurement tool, follow-up time, statistical analysis method, both significant and non-significant factors associated with fatigue and strength of association.

### Quality assessment

The National Heart, Lung, and Blood Institute (NHLBI) quality appraisal tool, a widely used assessment tool recommended by Cochrane for evaluating qualities of observational and cross-sectional studies, was used to evaluate internal validity and risk of bias [28, 29]. The NHLBI comprises 14 items, of which 10 are applicable to cross-sectional studies, and all 14 items are applicable to observational cohort studies. Each item was scored independently by two authors (H.O.F. and O.A.I.). The NHLBI tool allowed for assessment of methodological flaws, such as sampling, adjustment for confounders, study power and other relevant factors for each study. The overall assessment of studies was rated as high, moderate or low based on the risk of bias. In order to capture limitations within the current evidence, no studies were excluded based on the quality assessment.

### Data synthesis

There was no meta-analysis performed owing to the high heterogeneity levels with regard to study population, identified factors and fatigue outcome measurements. Two authors (H.O.F. and O.A.I.) independently grouped and classified the identified factors into individual, disease-specific, psychosocial, behavioural and biological groups (Supplementary Table S2, available at *Rheumatology Advances in Practice* online) using the bio-behavioural conceptual framework of fatigue in OA [20, 21]. The synthesis decisions were reviewed until both authors reached consensus.

The findings were presented using a narrative synthesis to report factors that were or were not associated with fatigue, and we performed a best evidence synthesis of factors that were investigated in two or more studies and ranked evidence grading based on previous studies [30–32] to grade the level of evidence supporting the associations (Supplementary Table S3, available at *Rheumatology Advances in Practice* online). Equally, we classified studies according to study design, with the preferred design being cohort study followed by case-control design and, lastly, cross-sectional design. We then ranked the studies according to their

methodological quality score. Also, identified factors were classified with the direction and strength of association using correlation or standardized coefficient as weak (<0.3), moderate ( $\geq 0.3$  to <0.7) and strong associations ( $\geq 0.7$ ) [33] or with odds ratios [34] where these were reported. We adjudged results as consistent if the factor was significantly associated with fatigue in the same direction of the association. In studies where only unstandardized coefficients were presented, we calculated the standardized beta ( $\beta$ ) coefficient using this formula:  $\beta = [(\text{standard deviation of independent variable}) / (\text{standard deviation of dependent variable})] \times \text{unstandardized (B) coefficient}$ .


## Results

Database searches identified a total of 1106 articles, which were exported to Refworks, where duplicates were removed. Removal of duplicates, screening for title and abstracts yielded a total of 68 articles for full screening. Twenty-four articles met the inclusion criteria and were included in the review (Fig. 1).

The 24 studies included a total of 9475 patients with knee and/or hip OA (Supplementary Table S4, available at *Rheumatology Advances in Practice* online). Diagnosis of OA in most of the included studies ( $n=20$ ; 83%) was according to ACR criteria or KL grading [6, 9, 10, 13, 18, 19, 35–48]. The remaining four studies confirmed OA based on a physician or rheumatologist diagnosis [49–52]. Included study designs were cross-sectional ( $n=13$ , 54.2%), cohort ( $n=9$ , 37.5%) or case-control ( $n=2$ , 8.3%). However, because the two case-control studies presented either a 5-day repeated longitudinal [18] or cross-sectional design [19] for data on the association between factors identified and fatigue, we used the cohort or cross-sectional quality appraisal for these two studies [18, 19]. Sample size varied considerably across studies, ranging from 68 [35] to 3815 participants [49]. Within the 24 eligible studies, there were 16 fatigue measurement tools used. The visual analog scale (VAS) was the most common outcome measure used (seven studies, 29.2%) to assess fatigue in the studies included; however, VAS anchors varied. Measurement tools for identified factors based on bio-behavioural groupings are presented in Supplementary Table S5, available at *Rheumatology Advances in Practice* online. Statistical analyses methods used in included studies comprised multiple linear regression models (i.e. backwards eliminations, hierarchical), logistic regression, Pearson's correlation, Spearman partial correlation, multilevel modelling, longitudinal mixed modelling and path analysis (Supplementary Table S4, available at *Rheumatology Advances in Practice* online).

### Quality assessment

Nineteen studies (nine cross-sectional [6, 9, 10, 19, 37, 44, 46, 49, 51] and 10 longitudinal [13, 18, 38–42, 48, 50, 52]) were rated as having high quality. Four studies

**Fig. 1** Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram

(three cross-sectional [35, 36, 47] and one longitudinal [45]) were of moderate quality, and one had low quality (cross-sectional [43]). The potential risks of bias in most studies were lack of sample size determination or power calculation ( $n=21$ ) and blinding of outcome assessors ( $n=24$ ) [Table 1]. The four studies rated as moderate quality lacked clear specification and definition of study populations and inadequate report of the rate of eligible participants [35, 36, 45, 47] or lacked control for confounders [45]. The study rated low quality [43] lacked clarity on the study population, inadequate report of the rate of eligible participants, and lack of adjustment for confounders.

#### Association between identified factors and fatigue

Factors associated with fatigue, with the direction and strength of association and levels of best evidence, are summarized in Figs 2–4 and Table 2, respectively. Identified factors based on the bio-behavioural framework are depicted in Supplementary Fig. S1, available at *Rheumatology Advances in Practice* online.

#### Individual factors

Ten studies investigated the association between individual factors (i.e. age, sex, education, BMI, race, living situation, living circumstances, monthly bill payment, financial status, co-morbidities, illness burden, activity-limiting co-morbidities, diabetes, hypertension, back pain, depression, sarcopenia, health status and vitality) and fatigue in five cross-sectional [10, 19, 37, 46, 49] and five longitudinal cohort studies [38, 40, 41, 48, 50]. Two individual factors (age and BMI) had moderate evidence of no association with fatigue. Moderate evidence was found for the association between high co-morbidities/illness burden and higher fatigue. There was limited evidence of no association between race (being

Black or non-Hispanic White) and level of education and fatigue, and there was conflicting evidence for the association between sex (being female) and fatigue. The remaining identified individual factors had insufficient evidence on their association with fatigue because results were reported from single studies (Supplementary Table S6, available at *Rheumatology Advances in Practice* online).

#### Disease-specific factors

Sixteen studies (8 cross-sectional [6, 19, 35, 37, 43, 44, 49, 51] and 8 longitudinal [13, 38, 40–42, 45, 48, 50]) examined the relationship between disease-specific factors (i.e. pain, momentary pain, hip pain, pain impact, OA symptoms and disability, pain-adjusted physical activity, joint stiffness, disability, knee strength, radiographic OA severity, baseline fatigue and quality of life) and fatigue. There was moderate evidence to support the association between high pain and higher fatigue. Limited evidence was found for the association between high momentary pain, high baseline fatigue and high disability with higher fatigue, and there was limited evidence of no association between radiographic OA severity and fatigue. Conflicting evidence was noted for the association between joint stiffness and fatigue. There was insufficient evidence for the association between fatigue and the remaining disease-specific factors (Supplementary Table S6, available at *Rheumatology Advances in Practice* online).

#### Psychosocial factors

A total of 11 studies assessed the association between psychosocial factors (i.e. depressive symptoms, anxiety, emotional well-being, pain catastrophizing, coping behaviours and social support) and fatigue, of which five were cross-sectional [9, 19, 37, 44, 49] and six were longitudinal [38, 40–42, 48, 50]. Strong evidence was



**TABLE 1** National Heart, Lung and Blood Institute (NHLBI) quality assessment for observational cohort and cross-sectional studies (24 studies)

| Authors                             | Q1 | Q2 | Q3 | *Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Q14 | Overall grade |
|-------------------------------------|----|----|----|-----|----|----|----|----|----|-----|-----|-----|-----|-----|---------------|
| Wolfe (1999) [6]                    | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Creamer <i>et al.</i> (1999) [35]   | Y  | N  | NR | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | Moderate      |
| Creamer <i>et al.</i> (2000) [36]   | Y  | N  | NR | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | Moderate      |
| Wolfe <i>et al.</i> (2004) [49]     | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N   | Y   | NR  | N/A | Y   | High          |
| Sale <i>et al.</i> (2008) [9]       | Y  | Y  | Y  | Y/Y | Y  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Murphy <i>et al.</i> (2008) [18]    | Y  | Y  | Y  | Y/Y | N  | Y  | Y  | Y  | Y  | Y   | Y   | NR  | Y   | Y   | High          |
| Murphy <i>et al.</i> (2010) [19]    | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N   | Y   | NR  | N/A | N   | High          |
| Stebbing <i>et al.</i> (2010) [37]  | Y  | Y  | Y  | Y/Y | Y  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Snijders <i>et al.</i> (2011) [13]  | Y  | Y  | Y  | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | N   | Y   | Y   | High          |
| Hawker <i>et al.</i> (2011) [38]    | Y  | Y  | Y  | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | NR  | Y   | Y   | High          |
| van Dijk <i>et al.</i> (2011) [39]  | Y  | Y  | Y  | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | N   | Y   | Y   | High          |
| Murphy <i>et al.</i> (2013) [40]    | Y  | Y  | Y  | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | N   | Y   | Y   | High          |
| Murphy & Kratz (2014) [41]          | Y  | Y  | Y  | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | NR  | Y   | Y   | High          |
| Zullig <i>et al.</i> (2015) [10]    | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Smith & Parmelee (2016) [50]        | Y  | Y  | Y  | N/Y | N  | Y  | Y  | Y  | Y  | Y   | Y   | CD  | Y   | Y   | High          |
| Carlesso <i>et al.</i> (2016) [42]  | Y  | Y  | Y  | Y/Y | N  | Y  | Y  | Y  | Y  | N   | Y   | NR  | Y   | Y   | High          |
| Huang <i>et al.</i> (2017) [43]     | Y  | Y  | NR | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | N   | Low           |
| Allen <i>et al.</i> (2019) [51]     | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Aree-Ue <i>et al.</i> (2019) [44]   | Y  | Y  | Y  | Y/Y | Y  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | N   | High          |
| Smith <i>et al.</i> 2019 [52]       | Y  | Y  | Y  | N/Y | N  | Y  | Y  | Y  | Y  | Y   | Y   | NR  | Y   | Y   | High          |
| Fu <i>et al.</i> (2019) [45]        | Y  | NR | NR | Y/Y | N  | N  | Y  | Y  | Y  | Y   | Y   | NR  | N   | Y   | Moderate      |
| Vlietstra <i>et al.</i> (2019) [46] | Y  | Y  | Y  | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | High          |
| Martinez <i>et al.</i> (2019) [47]  | Y  | N  | NR | Y/Y | N  | N  | N  | Y  | Y  | N/A | Y   | NR  | N/A | Y   | Moderate      |
| Fawole <i>et al.</i> (2020) [48]    | Y  | Y  | Y  | Y/Y | N  | Y  | Y  | Y  | Y  | N   | Y   | NR  | Y   | Y   | High          |

\*Same population/uniform eligibility. CD: cannot determine; N: no; N/A: not applicable; NR: not reported; Y: yes. Q1: was the research question or objective clearly stated? Q2: was study population clearly specified and defined? Q3: was the participation rate of eligible persons  $\geq 50\%$ ? Q4: were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study pre-specified and applied uniformly to all participants? Q5: was a sample size justification, power description, or variance and effect estimates provided? Q6: for the analysis, were the exposure(s) of interest measured prior to the outcome(s) being measured? Q7: was the time frame sufficient that one could reasonably expect to see an association between exposure and outcome if it existed? Q8: for exposures that vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g. categories of exposure, or exposure measured as continuous variable)? Q9: were the exposure measures (independent variables) clearly defined, valid, reliable and implemented consistently across all study participants? Q10: was the exposure(s) assessed more than once over time? Q11: were the outcome measures (dependent variables) clearly defined, valid, reliable and implemented consistently across all study participants? Q12: were the outcome assessors blinded to the exposure status of participants? Q13: was loss to follow-up after baseline  $\leq 20\%$ ? Q14: were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

found for the association between high depressive symptoms and higher fatigue. Limited evidence was noted for the association between high pain catastrophizing and higher fatigue. There was conflicting evidence on the association between anxiety and social support with fatigue. Emotional well-being and coping behaviours had insufficient evidence on their association with fatigue based on findings from single studies.

#### Behavioural factors

Fifteen studies investigated the association between behavioural factors (i.e. self-reported physical function, performance-based physical function, aerobic function,

physical activity, momentary pacing behaviour and sleep) and fatigue in seven cross-sectional [6, 19, 36, 37, 43, 44, 47] and eight longitudinal studies [13, 18, 38–41, 48, 52]. Strong evidence was found for the association between low self-reported physical function and higher levels of fatigue. There was moderate evidence that low physical activity is associated with higher fatigue. There was conflicting evidence on the association between performance-based physical function and sleep with fatigue. There was insufficient evidence for the association between aerobic function and momentary pacing behaviour with fatigue levels because this was reported in only one study for each of these factors.

Fig. 2 Strength of association between individual and biological factors identified and fatigue

| Fatigue               | Comorbidities<br>1Illness burden<br>2Activity-limiting comorbidity<br>3Diabetes<br>4Hypertension<br>5Back pain<br>6Depression<br>7Sarcopenia | Health status | Vitality       | Race           | 8Living circumstances<br>9Living situation | 10Financial status<br>11Monthly bill payment | Age            | Sex            | Body Mass index | Education      | Systemic inflammation |
|-----------------------|--|---------------|----------------|----------------|--|--|----------------|----------------|-----------------|----------------|-----------------------|
| <b>Studies</b>        |  |               |                |                |  |  |                |                |                 |                |                       |
| Murphy et al 2013     | ++ <sup>1,2</sup>  |               |                |                |  |  | 0 <sup>1</sup> |                | 0 <sup>1</sup>  |                |                       |
| Murphy & Kratz 2014   | ++ <sup>1,2</sup>  |               |                |                |  |  | 0 <sup>1</sup> | 0 <sup>1</sup> | 0 <sup>1</sup>  |                |                       |
| Zullig et al 2015     | 0 <sup>1</sup>   |               |                |                |  | ψ <sup>1</sup>                               | ψ <sup>1</sup> |                | ψ <sup>1</sup>  |                |                       |
| Hawker et al 2011     | ψ <sup>1</sup>   |               | ψ <sup>1</sup> |                |  | ψ <sup>1</sup>                               | ψ <sup>1</sup> |                |                 | ψ <sup>1</sup> |                       |
| Fawole et al 2020     | ψ <sup>1</sup>   |               |                |                |  | 0 <sup>1</sup>                               | 0 <sup>1</sup> | 0 <sup>1</sup> | 0 <sup>1</sup>  |                |                       |
| Vlietstra et al 2019  | 0 <sup>1</sup>   |               |                |                |  |  |                |                |                 |                |                       |
| Murphy & Smith 2010   |  |               |                | ψ <sup>1</sup> |  |  |                |                | ++ <sup>1</sup> |                |                       |
| Smith & Parmelee 2016 |  |               |                | 0 <sup>1</sup> |  |  | 0 <sup>1</sup> | 0 <sup>1</sup> | 0 <sup>1</sup>  | 0 <sup>1</sup> |                       |
| Wolfe et al 2004      |  |               |                |                |  |  | 0 <sup>1</sup> | 0 <sup>1</sup> |                 |                | ψ <sup>1</sup>        |
| Stebbins et al 2010   |  |               |                |                |  |  | 0 <sup>1</sup> |                |                 |                | ψ <sup>1</sup>        |

+ = weak positive association (<0.3); ++ = moderate positive association (>0.3 to <0.7); +++ = strong positive association (>0.7); 0 = Non-significant  
 - = weak negative association (<0.3); -- = moderate negative association (>0.3 to <0.7); --- = strong negative association (>0.7)  
 ψ = unadjusted analysis; 1 = odds ratio; ψ = No coefficient of association or non-association reported; All associations are adjusted analysis unless otherwise indicated.  
 Positive association (blue), Negative association (yellow), Non-significant (NS) (red)

Odds ratio were interpreted as weak association (< 1.5 or > 0.59) = <0.2; moderate association (1.6 to 5 or 0.59 to 0.29) = 0.3 to 0.7; strong association (>5 or <0.15) = >0.8 [34]

Associations are presented as correlation (r) or standardized (β) coefficients or odd ratios (OR).

Fig. 3 Strength of association between disease-specific factors and fatigue

| Fatigue               | Pain              | Momentary pain   | Hip pain        | Pain impact    | OA symptoms & disability (WOMAC total) | Pain-adjusted physical activity metrics | Joint stiffness | Disability      | Knee strength  | OA severity (radiographic) | Baseline Fatigue | Quality of life |
|-----------------------|-------------------|------------------|-----------------|----------------|--|---|-----------------|-----------------|----------------|----------------------------|------------------|-----------------|
| <b>Studies</b>        |                   |                  |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Wolfe 1999            | ++ <sup>a</sup>   |                  |                 |                |  |   | ++ <sup>a</sup> |                 |                |                            |                  |                 |
| Creamer et al 1999    | ψ <sup>1</sup>    |                  |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Wolfe et al 2004      | ++ <sup>a</sup>   |                  |                 |                |  |   |                 | +               |                |                            |                  |                 |
| Stebbins et al 2010   | 0 <sup>1</sup>    |                  |                 |                |  |   | ψ <sup>1</sup>  | ++ <sup>a</sup> |                | 0 <sup>1</sup>             |                  |                 |
| Murphy & Smith 2010   |                   | +++ <sup>a</sup> |                 |                |  |   |                 | +               | 0 <sup>1</sup> | 0 <sup>1</sup>             |                  |                 |
| Hawker et al 2011     | ψ <sup>1</sup>    |                  |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Snijders et al 2011   | 0 <sup>1</sup>    |                  |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Murphy et al 2013     | ++ <sup>a</sup>   | +++ <sup>a</sup> |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Murphy & Kratz 2014   | ++ <sup>a</sup>   |                  |                 |                |  |   |                 |                 |                |                            | ++               |                 |
| Smith & Parmelee 2016 | +                 | ++               |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Huang et al 2017      | ++ <sup>a,c</sup> |                  |                 |                |  |   |                 |                 |                |                            |                  |                 |
| Allen et al 2019      | ++                |                  |                 |                |  | +                                       | 0 <sup>1</sup>  |                 |                |                            |                  |                 |
| Aree-Ue et al 2019    | ++ <sup>a</sup>   |                  |                 |                |  |   |                 |                 |                |                            |                  | ψ <sup>1</sup>  |
| Fawole et al 2020     | 0 <sup>1</sup>    |                  |                 |                |  |   |                 |                 |                | 0 <sup>1</sup>             | ++               | ψ <sup>1</sup>  |
| Fu et al 2019         |                   |                  | ++ <sup>a</sup> |                |  |   |                 |                 |                |                            |                  | ψ <sup>1</sup>  |
| Carlesso et al 2016   |                   |                  |                 | 0 <sup>1</sup> | ++ <sup>a</sup>                        |   |                 |                 |                |                            |                  | ψ <sup>1</sup>  |

+ = weak positive association (<0.3); ++ = moderate positive association (>0.3 to <0.7); +++ = strong positive association (>0.7); 0 = Non-significant  
 - = weak negative association (<0.3); -- = moderate negative association (>0.3 to <0.7); --- = strong negative association (>0.7)  
 ψ = unadjusted analysis; 1 = odds ratio; ψ = No coefficient of association or non-association reported; All associations are adjusted analysis unless otherwise indicated.  
 a = both knee & hip OA; b = Significant correlation between fatigue and McGill pain scale but not for WOMAC and VAS pain scales  
 c = Significant positive correlation between pain and fatigue dimensions (general, physical, mental fatigue and reduced activity) except reduced motivation; + = Significant association for pain-adjusted activity types (pain-adjusted step count, energy expenditure, all activity, light intensity) except for moderate intensity physical activity  
 OA = Osteoarthritis; WOMAC = Western Ontario McMaster and Universities Osteoarthritis Index; VAS= Visual analogue scale

Positive association (blue), Negative association (yellow), Non-significant (NS) (red)

Odds ratio were interpreted as weak association (< 1.5 or > 0.59) = <0.2; moderate association (1.6 to 5 or 0.59 to 0.29) = 0.3 to 0.7; strong association (>5 or <0.15) = >0.8 [34]

Associations are presented as correlation (r) or standardized (β) coefficients or odd ratios (OR).

Biological factor

Of the 24 studies, only a cross-sectional study included a biological factor, CRP, a measure of systemic inflammation [37], rendering the evidence on the association between systematic inflammation (CRP) and fatigue to be insufficient (Supplementary Table S6, available at *Rheumatology Advances in Practice* online).

Discussion

The aim of this systematic review was to summarize current epidemiological evidence of potential factors associated (correlates and predictors) with fatigue in people with hip and/or knee OA using the bio-behavioural conceptual framework. Owing to high levels of

Fig. 4 Strength of association between psychosocial and behavioural factors and fatigue

| Fatigue               | Depressive symptoms | Anxiety         | Emotional well-being (momentary affect) | PC              | Coping behaviours | Social support | Subjective PF                      | Objective PF<br>TUG<br>6-MW<br>10-MTW<br>20-MWT | Aerobic function (VO <sub>2</sub> ) | PA             | Momentary pacing behaviours | Sleep           |
|-----------------------|---------------------|-----------------|---|-----------------|-------------------|----------------|------------------------------------|---|-------------------------------------|----------------|-----------------------------|-----------------|
| <b>Studies</b>        |                     |                 |   |                 |                   |                |                                    |   |                                     |                |                             |                 |
| Wolfe et al 2004      | ++ <sup>†</sup>     |                 |   |                 |                   |                |                                    |   |                                     |                |                             |                 |
| Sale et al 2008       | +                   |                 |   |                 |                   |                |                                    |   |                                     |                |                             |                 |
| Stebbing et al 2010   | ++ <sup>†</sup>     | ++ <sup>†</sup> |   |                 |                   |                | ψ                                  |   |                                     |                |                             | ++ <sup>†</sup> |
| Murphy & Smith 2010   | 0 <sup>†</sup>      | 0               |   |                 |                   |                | ++ <sup>†</sup>                    | 0 <sup>†</sup> 1,2                              |                                     |                |                             | +               |
| Hawker et al 2011     | +++                 |                 |   | ψ               | ψ                 | ψ              | ψ                                  |   |                                     |                |                             |                 |
| Murphy et al 2013     | ++ <sup>†</sup>     |                 |   |                 |                   |                | ++ <sup>†</sup>                    | 0 <sup>†</sup> 1,2                              | -1                                  | --             |                             | 0 <sup>†</sup>  |
| Murphy & Kratz 2014   | ++ <sup>†</sup>     |                 |   |                 |                   |                | 0 <sup>†</sup> 1,2                 | 0 <sup>†</sup> 1,2                              |                                     | 0 <sup>†</sup> | ++ <sup>†</sup>             |                 |
| Smith & Parmelee 2016 | +                   |                 | -- <sup>h</sup>                         |                 |                   |                |                                    |   |                                     | 0              | +                           |                 |
| Carlesso et al 2016   | ++ <sup>†</sup>     | ++ <sup>†</sup> |   | ++ <sup>†</sup> |                   | 0 <sup>†</sup> |                                    |   |                                     |                |                             |                 |
| Aree-Ue et al 2019    | ++ <sup>†</sup>     |                 |   |                 |                   |                | 0 <sup>†</sup> 1,2                 |   |                                     |                |                             |                 |
| Fawole et al 2020     | +                   |                 |   | 0               |                   |                |                                    | -1  |                                     |                |                             | 0               |
| Wolfe 1999            |                     |                 |   |                 |                   |                | ++ <sup>†</sup>                    |   |                                     |                |                             |                 |
| Creamer et al 2000    |                     |                 |   |                 |                   |                | ++ <sup>†</sup>                    |   |                                     |                |                             |                 |
| Snidjers et al 2011   |                     |                 |   |                 |                   |                | 0                                  |   |                                     |                |                             |                 |
| Van Dijk et al 2011   |                     |                 |   |                 |                   |                | ++ <sup>†</sup> 0 <sup>†</sup> 1,2 | -- <sup>h</sup> 1,2                             |                                     |                |                             |                 |
| Huang et al 2017      |                     |                 |   |                 |                   |                | 0 <sup>†</sup> 1,2                 | 0 <sup>†</sup> 1,2                              |                                     |                |                             |                 |
| Murphy et al 2008     |                     |                 |   |                 |                   |                | 0 <sup>†</sup> 1,2                 |   |                                     |                |                             |                 |
| Smith et al 2019      |                     |                 |   |                 |                   |                |                                    |   |                                     | --             |                             |                 |
| Martinez et al 2019   |                     |                 |   |                 |                   |                |                                    |   |                                     |                |                             | --              |

+ = weak positive association (<0.3); ++ = moderate positive association (≥0.3 to <0.7); +++ = strong positive association (≥0.7); 0 = Non-significant  
 - = weak negative association (<0.3); -- = moderate negative association (≥0.3 to <0.7); --- = strong negative association (≥0.7)  
 † = unadjusted analysis; ‡ = odds ratio; ψ = No coefficient of association or non-association reported; All associations are adjusted analysis unless otherwise indicated.  
 ‡ = Momentary fatigue; † = Mean fatigue; ‡ = Checklist Individual Strength (CIS)-fatigue; † = CIS-activity; \* = cross-sectional analysis; ‡ = longitudinal analysis  
 ‡ = Significant positive correlations between self-reported physical function and fatigue dimensions (i.e., general, physical, reduced motivation and activity); † = Mental fatigue was non-significant; ‡ = hip osteoarthritis (OA); † = knee OA; ‡ = both knee & hip OA  
 PC = Pain catastrophizing; PF = physical function; PA = Physical activity; TUG = Timed up and go; 6-MW = six-minute walk; 10-MTW = 10-meter timed walk; 20-MWT = 20-meter walk test  
 Positive association (blue), Negative association (yellow), Non-significant (NS) (red)

Odds ratio were interpreted as weak association (≤ 1.5 or ≥ 0.59) = <0.2; moderate association (1.6 to 5 or 0.59 to 0.29) = 0.3 to 0.7; strong association (>5 or ≤0.15) = ≥0.8 [34]

Associations are presented as correlation (r) or standardized (β) coefficients or odd ratios (OR).

heterogeneity in study designs, fatigue measurement tools and factors identified, the review used a narrative and best evidence synthesis, which enabled the grading of factors into different levels of evidence. There were 24 studies that evaluated factors associated with fatigue in people with hip and/or knee OA, with the majority having cross-sectional designs.

The best evidence synthesis found strong evidence for the association between poor self-reported physical function and high depressive symptoms with higher fatigue levels. Moderate evidence was found for the association between a high number of co-morbidities or illness burden, high pain and low physical activity with higher fatigue. Moderate or limited evidence was noted for no association between sociodemographic factors (age, education, race, living situation or circumstances), BMI and radiographic OA severity with fatigue. Conflicting evidence was found for the association between poor performance-based physical function, high anxiety, high joint stiffness, poor sleep and low social support with higher fatigue. Limited or insufficient evidence was available for a majority of the disease-specific factors identified, suggesting

that it is unclear whether fatigue pathways for those with hip and/or knee OA differ from fatigue pathways in other pathological states. Our discussion will focus on factors identified as having strong, moderate or inconclusive evidence and notable exceptions.

The findings of this review underscore the importance of modifiable factors, including perceived physical function, depressive symptoms, pain and physical activity, as potential targets for consideration in fatigue management in patients with hip and/or knee OA, because the relationships between these factors and fatigue were supported by strong or moderate levels of evidence. Generally, people with hip and knee OA have a high prevalence of low physical function [53], high depressive symptoms [54], severe pain [55] and low physical activity [56]. When present, these modifiable factors are reported to worsen health outcomes and quality of life in this population [57–61]. Thus, their inclusion as potential treatment targets might be important in the design of treatment plans and for optimal fatigue management. A previous review on fatigue interventions identified non-pharmacological interventions, such as exercise and



**TABLE 2** Overview and best evidence synthesis regarding associations with a high level of fatigue in hip and/or knee OA

| At least two studies                                      | Association found   | No association found   | Best evidence                       |
|---|---|--|-------------------------------------|
| <b>Individual factors</b>                                 |   |  |                                     |
| Older age   | One HQ cohort study and one HQ cross-sectional study [37, 38]<br>One HQ cross-sectional study reported an association but did not indicate the direction of association, and this has not been included in the evidence synthesis [10] <sup>†</sup> | Four HQ cohort studies, two HQ cross-sectional studies [37, 40, 41, 48–50]   | Moderate evidence of no association |
| Sex (being female)  | Female<br>One HQ cohort study [38]  | Female<br>Two HQ cohort studies [41, 48]<br>One HQ cohort study did not report which of the gender type (male or female) had no association with fatigue [50] <sup>*</sup> | Conflicting evidence                |
| High BMI  | One HQ cross-sectional study [19]<br>One HQ cross-sectional study reported no direction of association, and this has not been included in the evidence synthesis [10] <sup>†</sup>  | Four HQ cohort studies [40, 41, 48, 50]  | Moderate evidence of no association |
| Education levels  | –   | Two HQ cohort studies [38, 50]   | Limited evidence of no association  |
| Race (being Black or non-Hispanic White)                  | –   | Two HQ cohort studies [48, 50]   | Limited evidence of no association  |
| Living circumstances/situation                            | –   | Two HQ cohort studies [38, 48]   | Limited evidence of no association  |
| High co-morbidities/illness burden                        | Four HQ cohort studies [38, 40, 41, 48] and one HQ cross-sectional study [10]   | One HQ cohort studies [41]   | Moderate evidence of association    |
| <b>Disease-specific factors</b>                           |   |  |                                     |
| High pain   | Three HQ cohort studies and seven HQ, one MQ and one LQ cross-sectional studies [6, 19, 35, 37, 38, 41, 43, 44, 49–51]  | Two HQ cohort studies and one HQ, one MQ, and one LQ cross-sectional studies [13, 35, 37, 43, 48]  | Moderate evidence of association    |
| High momentary pain                                       | One HQ cohort study and two HQ cross-sectional studies [19, 40, 50]   | –  | Limited evidence of association     |
| High joint stiffness                                      | Two HQ cross-sectional studies [6, 37]  | One HQ cross-sectional study [37]  | Conflicting evidence                |
| High disability   | Two HQ cross-sectional studies [37, 49]   | –  | Limited evidence of association     |
| Worse radiographic OA severity (Kellgren–Lawrence scores) | –   | One HQ cohort study and two HQ cross-sectional studies [19, 37, 48]  | Limited evidence of no association  |
| High baseline fatigue                                     | One HQ cohort study and one HQ cross-sectional study [41, 48]   | –  | Limited evidence of association     |
| <b>Psychosocial factors</b>                               |   |  |                                     |
| High depressive symptoms                                  | Six HQ cohort studies and four HQ cross-sectional studies [9, 10, 37, 38, 40–42, 48–50]   | One HQ cohort study and one HQ cross-sectional study [19, 41]  | Strong evidence of association      |
| High anxiety  | One HQ cohort study and one cross-sectional study [37, 42]  | One HQ cross-sectional study [37]  | Conflicting evidence                |
| High pain catastrophizing                                 | Two HQ cohort studies [38, 42]  | One HQ cohort study [48]   | Limited evidence of association     |
| Low social support  | One HQ cohort study [38]  | One HQ cohort study [42]   | Conflicting evidence                |

(continued)

TABLE 2 Continued

| At least two studies                     | Association found   | No association found   | Best evidence                    |
|--|---|--|----------------------------------|
| <b>Behavioural factors</b>               |   |  |                                  |
| Poor self-reported physical function     | Four HQ cohort studies and six HQ cross-sectional studies, one MQ and one LQ cross-sectional study [6, 13, 19, 36–40, 43, 49] | One HQ, one MQ and one LQ cross-sectional study [36, 37, 43]         | Strong evidence of association   |
| Poor performance-based physical function | Three HQ cohort studies and one HQ cross-sectional study [39, 40, 44, 48]   | Three HQ cohort studies and one HQ cross-sectional study [19, 39–41] | Conflicting evidence             |
| Low physical activity                    | Three HQ cohort studies [18, 40, 52]  | One HQ cohort study [41]   | Moderate evidence of association |
| Poor sleep                               | One HQ cross-sectional study and one MQ cross-sectional study [37, 47]  | Two HQ cohort studies [40, 48]                                       | Conflicting evidence             |

\*Note that other factors identified from only one study and/or where directions of association have not been stated have not been included in this evidence synthesis. HQ: high quality; LQ: Low quality; MQ: moderate quality.

cognitive behavioural therapies, as the common and likely interventions for reduction of fatigue [62]. Both interventions are also used to decrease the negative impact of high levels of depressive symptoms, severe pain and poor physical function [63, 64] and, as such, might influence fatigue reduction in hip and knee OA. However, owing to limited longitudinal studies in the present review, future studies are warranted to ascertain the predictive nature of these modifiable factors on fatigue.

In general, co-morbidities or illness burden was positively associated with increased fatigue, suggesting that the presence of co-morbidities or illness burden might worsen fatigue. Furthermore, epidemiological evidence indicates that co-morbidities escalate the impact of OA and, accordingly, worsen OA symptoms in the long term [65].

Surprisingly, the radiographic severity of hip or knee OA was not significantly associated with fatigue. This lack of significant association implies that the amount of articular damage around the knee or hip joint seems to be unrelated to fatigue. Likewise, this lack of association between radiographic evidence and fatigue has been reported for the RA population [37]. The premise that radiographic evidence of OA does not always equate to symptoms in OA [66, 67] might be a plausible reason for our finding. Furthermore, there are strong speculations that OA is a multifactorial entity with multiple phenotypes [68, 69], and it is possible that structural phenotypes do not play a role in fatigue symptomatology in OA. This finding might be of clinical importance for researchers planning future studies of fatigue and lower limb OA, because this result of no association also suggests that objective measures of hip or knee OA severity or KL score might not be a determinant or prognosticator for fatigue, which has the potential to reduce study costs. However, the current evidence level is limited owing to the availability of two cross-sectional studies and one longitudinal study.

It is important to note that although there was moderate evidence of no association between age, BMI and

fatigue, these findings might have been impacted by the variation in fatigue assessment tools in the studies included; nonetheless, our findings are similar to those of prior research in rheumatological conditions [70, 71]. Moreover, four of the six studies included in the best evidence synthesis for BMI and fatigue were longitudinal studies, but only one had a long follow-up time (2 years) [48], with others averaging 5–7 days. It is unlikely that the effect of BMI on fatigue could be detected within such a short temporal scale.

The association of self-reported physical function, depressive symptoms and pain with fatigue is in accordance with previous research [70, 72]. The strong and moderate evidence found for these factors highlights the fact that fatigue is associated with clinical and generic factors that are modifiable and, as such, might have implications for clinical management of fatigue in this population. In contrast, inconclusive evidence was noted for the relationship between performance-based physical function and fatigue relative to the strong evidence found for subjective physical function. One explanation could be attributable to the high numbers of studies that investigated the relationship between subjective physical function and fatigue. Another explanation could be related to the different measures used to evaluate performance-based function (i.e. timed up and go, 6 min walk, and 10 and 20 m timed walk) and the dependence on only two traditional longitudinal studies. The mismatch between objective performance-based findings and subjective measures warrants the need for both physical function measures to be included in fatigue studies until studies elucidate causes and ways to adjust for differences in perception and performance of physical function in the hip and knee OA population.

Likewise, mixed evidence was noted for sleep, female sex and joint stiffness with fatigue. The inconclusive finding for sleep and fatigue is similar to findings for the RA population [70], suggesting that the relationship between sleep and fatigue is not well understood. However, this mixed evidence on the relationship

between sleep with fatigue could be attributable to different sleep constructs measured in the included studies (sleep quality [47, 48] or sleep disturbance [37] or sleep efficiency [40]). Also, variation in fatigue tools could have led to the conflicting evidence, because studies that used more comprehensive fatigue tools (e.g. SF-12 vitality scale or multidimensional assessment of fatigue–global fatigue index) found a significant association relative to those that used a single numerical rating scale or VAS. On the contrary, our conflicting findings between the relationship of female sex and fatigue conflict with that of a previous review [70]. These results between female sex and fatigue might differ because of the different pathways of RA and OA. RA includes both a genetic and an environmental pathway [73], whereas OA also includes other pathways of aetiology, such as traumatic injury or repetitive joint over-use [74]. Moreover, the majority of the studies that reported no association between fatigue and sex used numerical rating scales to measure fatigue. In the future, studies that evaluate fatigue should include information on the type of OA (primary or secondary) and assess fatigue with more comprehensive fatigue instruments. Most of the inconclusive evidence regarding joint stiffness and fatigue might be attributable to the use of different fatigue instruments (15 cm VAS and multidimensional assessment of fatigue–global fatigue index) and studies not including objective measures for joint stiffness, such as joint range of movement or tendon elasticity. Moreover, emerging evidence suggests that altered tendon elasticity owing to structural deformity from pathology might increase the energy requirement during movement and, consequently, lead to fatigue [75, 76]. Although no conclusions have been drawn because work is ongoing, there are debates regarding available quantities of elastin in tendons and its potential role in initiation of fatigue. In OA, the research on systemic inflammation and fatigue is nascent [21], but this emerging evidence creates a basis for further investigation of the relationship between fatigue and OA. However, studies on other chronic diseases (e.g. chronic fatigue syndrome and type 2 diabetes) have evaluated the relationship between systemic inflammation and fatigue, with evidence suggesting that systemic inflammatory markers are positively associated with increased fatigue both cross-sectionally and over time [77, 78]. Thus, it could be hypothesized that systemic inflammation might lead to alteration of molecules that might adversely influence cell functions, thereby distorting cellular energy production and, consequently, leading to subjective feelings of fatigue [79].

### Strengths and limitations

Although our review is comprehensive and systematic and the first systematic review to be conducted on factors associated with fatigue in people with knee and/or hip OA, it has some limitations. Our search might have missed some studies that were published in non-English language journals; thus, other factors might not have

been identified. Owing to the high levels of heterogeneity with regard to study populations, identified factors and fatigue outcome measurement tools, a meaningful quantitative synthesis (meta-analysis) of effect estimates was not possible. Consequently, the adoption of the best evidence synthesis approach was the most appropriate in this review.

The fatigue measurement tools used in the included studies generally have positive and good psychometric properties [37, 80–82]; nonetheless, many of these fatigue tools have not been validated for the hip and knee OA population. Thus, the use of fatigue instruments designed for other rheumatic and chronic conditions (i.e. RA, multiple sclerosis, cancer) might lead to important issues, such as contamination bias [83]. Thus, there is a need for well-designed and validated fatigue instruments for hip and knee OA populations. Furthermore, the use of diverse fatigue measurement tools and different tools for factors identified might have influenced the associations found, consequently impacting our findings and limiting generalizations. Thus, we suggest that more studies should use uniform measures of fatigue. Although the NHBLI quality appraisal tool is valid for assessing internal validity and risk of bias in observational and cross-sectional studies [28, 29], there were other potential risks of bias that were not considered in the NHBLI. These include pre-definition of key confounders and consideration of adjustment for *a priori* key confounders and attrition bias (handling of missing data). Furthermore, although another study [20] has evaluated fatigue more broadly, there is a need to examine fatigue specifically in those with hip and knee OA and provide a starting point reference on the best evidence available in specific OA-related fatigue literature.

Strengths of this review included the robust classification of factors using the bio-behavioural conceptual framework of fatigue in OA and the best evidence synthesis as a means for amalgamating results. Given that meta-analysis was not possible, the best evidence synthesis and evidence grading of all the data from the systematic review is likely to help streamline future studies of fatigue through identification of factors that need to be researched further in order to deepen our understanding of fatigue within the hip and knee OA population. Although, the approach used for best evidence synthesis is a common one [30–32], this approach does not consider the methodological quality limitation within each study (i.e. whether the weaknesses identified lead to bias), thus results should be interpreted with caution. Furthermore, the use of a more recent Grading of Recommendation, Assessment, Development and Evaluation (GRADE) approach might have led to a more robust rating of certainty of evidence [84]; it was not feasible to apply this approach because fatigue was considered in this review as either an outcome or a predictor. This meant that studies differed in the predictors assessed, outcomes assessed and analytical approaches, resulting in heterogeneity in prediction models.

### Recommendation for future studies and practice

Current evidence strongly suggests that to manage fatigue in hip and knee OA, modifiable factors, such as physical function, depressive symptoms, pain and physical activity, need to be targeted. However, owing to the potential for circularity vs causality of fatigue, depression, pain and physical function, there is a need to investigate the potential longitudinal links between fatigue and these factors to enhance our understanding of fatigue aetiology in hip and knee OA. In contrast, older age, BMI and disease (OA) severity should not be targets for fatigue intervention. More studies that comprise rigorous longitudinal designs, a long-term follow-up period and consistent fatigue measures with adjustment for key confounders are warranted. This could lead to identification of predictors of fatigue and enhancement of current evidence. Also, given that the measurement of fatigue is incomplete without consideration for its multidimensionality, classifying fatigue in relationship to a specific activity with fixed intensity and duration provides a more objective approach to fatigue assessment [19, 85], a concept known as fatigability. Future studies should consider both assessment of fatigability and dimensions of fatigue in those with hip and knee OA. Equally, comprehensive investigations of disease-specific factors and other factors identified using the bio-behavioural conceptual framework are needed to provide more robust and comprehensive evidence on fatigue predictors over time.

### Conclusions

There is strong or moderate evidence that high numbers of co-morbidities or illness burden and modifiable factors, such as high depressive symptoms, low levels of self-reported physical function, high pain and low physical activity levels, are associated with greater fatigue, making these factors possible targets for fatigue reduction in hip and/or knee OA populations. More rigorous longitudinal studies are needed in order to substantiate the current evidence and to investigate the causal effect and directionality of other potential identified determinants of fatigue in order to understand the aetiology and mechanisms of fatigue within the knee and/or hip OA populations.

**Funding:** No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

**Disclosure statement:** The authors have declared no conflicts of interest.

### Data availability statement

Data are available upon reasonable request to the corresponding author. All data relevant to the study are included in the article.

### Supplementary data

Supplementary data are available at *Rheumatology Advances in Practice* online.

### References

- Vos T, Allen C, Arora M *et al*. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1545–602.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442.
- Pereira D, Peleteiro B, Araújo J *et al*. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. *Osteoarthritis Cartilage* 2011;19:1270–85.
- Leveille SG, Fried L, Guralnik JM. Disabling symptoms: what do older women report? *J Gen Intern Med* 2002; 17:766–73.
- Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. *J Rheumatol* 1996;23:1407–17.
- Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. *Rheumatology* 1999;38:355–61.
- Stebbing S, Treharne GJ. Fatigue in rheumatic disease: an overview. *Int J Clin Rheumatol* 2010;5:487–502.
- Power JD, Badley EM, French MR, Wall AJ, Hawker GA. Fatigue in osteoarthritis: a qualitative study. *BMC Musculoskelet Disord* 2008;9:63.
- Sale JEM, Gignac M, Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. *J Rheumatol* 2008;35:335–42.
- Zullig LL, Bosworth HB, Jeffreys AS *et al*. The association of comorbid conditions with patient-reported outcomes in Veterans with hip and knee osteoarthritis. *Clin Rheumatol* 2015;34:1435–41.
- Wysong, P. The institute of musculoskeletal health and arthritis. *Clin Invest Med* 2002;25:71–3.
- Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. *Clin Rheumatol* 2016;35:409–15.
- Snijders GF, van den Ende CHM, Fransen J *et al*.; Nijmegen OsteoArthritis Collaboration Study Group. Fatigue in knee and hip osteoarthritis: the role of pain and physical function. *Rheumatology* 2011;50: 1894–900.
- Cross M, Lapsley H, Barcenilla A, Brooks P, March L. Association between measures of fatigue and health-related quality of life in rheumatoid arthritis and osteoarthritis. *Patient* 2008;1:97–104.
- Aritake S, Kaneita Y, Ohtsu T *et al*. Prevalence of fatigue symptoms and correlations in the general adult population. *Sleep Biol Rhythms* 2015;13:146–54.
- Cullen W, Kearney Y, Bury G. Prevalence of fatigue in general practice. *Ir J Med Sci* 2002;171:10–2.
- Cathébras PJ, Robbins JM, Kirmayer LJ, Hayton BC. Fatigue in primary care: prevalence, psychiatric

- comorbidity, illness behavior, and outcome. *J Gen Intern Med* 1992;7:276–86.
- 18 Murphy SL, Smith DM, Clauw DJ, Alexander NB. The impact of momentary pain and fatigue on physical activity in women with osteoarthritis. *Arthritis Rheum* 2008;59:849–56.
- 19 Murphy SL, Smith DM. Ecological measurement of fatigue and fatigability in older adults with osteoarthritis. *J Gerontol A Biol Sci Med Sci* 2010;65:184–9.
- 20 Hackney AJ, Klinedinst NJ, Resnick B, Renn C, Fiskum G. A review and synthesis of correlates of fatigue in osteoarthritis. *Int J Orthop Trauma Nurs* 2019;33:4–10.
- 21 Hackney AJ, Klinedinst NJ, Resnick B, Johantgen M. Association of systemic inflammation and fatigue in osteoarthritis: 2007–2010 National Health and Nutrition Examination Survey. *Biol Res Nurs* 2019;21:532–43.
- 22 Ameringer S, Smith WR. Emerging biobehavioral factors of fatigue in sickle cell disease. *J Nurs Scholarsh* 2011;43:22–9.
- 23 Grady PA. A discussion with Patricia A. Grady on the 20th anniversary of the National Institute of Nursing Research. *J Nurs Scholar* 2006;38:208–12.
- 24 Moher D, Shamseer L, Clarke M *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- 25 McGowan J, Sampson M, Salzwedel DM *et al.* PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40–6.
- 26 Altman R, Asch E, Bloch D *et al.* Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. *Arthritis Rheum* 1986;29:1039–49.
- 27 Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis* 1957;16:494–502.
- 28 National Heart Lung and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. 2014. Available at: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>.
- 29 Carbia C, López-Caneda E, Corral M, Cadaveira F. A systematic review of neuropsychological studies involving young binge drinkers. *Neurosci Biobehav Rev* 2018;90:332–49.
- 30 Van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. *Spine* 2003;28:1290–9.
- 31 Yusuf E, Nelissen RG, Ioan-Facsinay A *et al.* Association between weight or body mass index and hand osteoarthritis: a systematic review. *Ann Rheum Dis* 2010;69:761–5.
- 32 Veenhof C, Huisman PA, Barten JA, Takken T, Pisters MF. Factors associated with physical activity in patients with osteoarthritis of the hip or knee: a systematic review. *Osteoarthritis Cartilage* 2012;20:6–12.
- 33 Hinkle D, Wiersma W, Jurs S. Applied statistics for the behavioural sciences. 3rd edn. Boston: Houghton Mifflin Company, 2003.
- 34 Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. *Commun Stat Simul Comput* 2010;39:860–4.
- 35 Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. *J Rheumatol* 1999;26:1785–92.
- 36 Creamer P, Lethbridge-Cejku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. *Rheumatology* 2000;39:490–6.
- 37 Stebbings S, Herbison P, Doyle TCH, Treharne GJ, Highton J. A comparison of fatigue correlates in rheumatoid arthritis and osteoarthritis: disparity in associations with disability, anxiety and sleep disturbance. *Rheumatology* 2010;49:361–7.
- 38 Hawker GA, Gignac MAM, Badley E *et al.* A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. *Arthritis Care Res* 2011;63:1382–90.
- 39 Van Dijk GM, Veenhof C, Lankhorst GJ, Van Den Ende CH, Dekker J. Vitality and the course of limitations in activities in osteoarthritis of the hip or knee. *BMC Musculoskelet Disord* 2011;12:269.
- 40 Murphy SL, Alexander NB, Levoska M, Smith DM. Relationship between fatigue and subsequent physical activity among older adults with symptomatic osteoarthritis. *Arthritis Care Res* 2013;65:1617–24.
- 41 Murphy SL, Kratz AL. Activity pacing in daily life: a within-day analysis. *Pain* 2014;155:2630–7.
- 42 Carlesso LC, Hawker GA, Waugh EJ, Davis AM. Disease-specific pain and function predict future pain impact in hip and knee osteoarthritis. *Clin Rheumatol* 2016;35:2999–3005.
- 43 Huang K-H, Hsieh R-L, Lee W-C. Pain, physical function, and health in patients with knee osteoarthritis. *Rehabil Nurs* 2017;42:235–41.
- 44 Aree-Ue S, Kongsombun U, Roopsawang I, Youngcharoen P. Path model of factors influencing health-related quality of life among older people with knee osteoarthritis. *Nurs Heal Sci* 2019;21:345–51.
- 45 Fu K, Makovey J, Metcalf B *et al.* Sleep quality and fatigue are associated with pain exacerbations of hip osteoarthritis: an Internet-based case-crossover study. *J Rheumatol* 2019;46:1524–30.
- 46 Vlietstra L, Stebbings S, Meredith-Jones K *et al.* Sarcopenia in osteoarthritis and rheumatoid arthritis: the association with self-reported fatigue, physical function and obesity. *PLoS One* 2019;14:e0217462.
- 47 Martinez R, Reddy N, Mulligan EP *et al.* Sleep quality and nocturnal pain in patients with hip osteoarthritis. *Medicine* 2019;98:e17464.
- 48 Fawole HO, Riskowski JL, Dell'Isola A *et al.* Determinants of generalized fatigue in individuals with symptomatic knee osteoarthritis: The MOST Study. *Int J Rheum Dis* 2020;23:559–68.



- 49 Wolfe F, Michaud K, Pincus T. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. *J Rheumatol* 2004;31: 2115–20.
- 50 Smith DM, Parmelee PA. Within-day variability of fatigue and pain among African Americans and non-Hispanic whites with osteoarthritis of the knee. *Arthritis Care Res* 2016;68:115–22.
- 51 Allen KD, Lo G, Abbate LM *et al.* Composite measures of physical activity and pain associate better with functional assessments than pain alone in knee osteoarthritis. *Clin Rheumatol* 2019;38:2241–7.
- 52 Smith DM, DeCaro JA, Murphy SL, Parmelee PA. Momentary reports of fatigue predict physical activity level: wrist, waist, and combined accelerometry. *J Aging Health* 2020;32:921–5.
- 53 Edwards MH, Van Der Pas S, Denkinger MD *et al.* Relationships between physical performance and knee and hip osteoarthritis: findings from the European Project on Osteoarthritis (EPOSA). *Age Ageing* 2014;43: 806–13.
- 54 Stubbs B, Aluko Y, Myint PK, Smith TO. Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. *Age Ageing* 2016; 45:228–35.
- 55 Neogi T. The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis Cartilage* 2013;21:1145–53.
- 56 Wallis JA, Webster KE, Levinger P, Taylor NF. What proportion of people with hip and knee osteoarthritis meet physical activity guidelines? A systematic review and meta-analysis. *Osteoarthritis Cartilage* 2013;21: 1648–59.
- 57 Tuominen U, Blom M, Hirvonen J *et al.* The effect of comorbidities on health-related quality of life in patients placed on the waiting list for total joint replacement. *Health Qual Life Outcomes* 2007;5:16.
- 58 Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol* 2016; 8:103–13.
- 59 Cross M, Smith E, Hoy D *et al.* The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73: 1323–30.
- 60 van Baar ME, Dekker J, Lemmens JAM, Oostendorp RAB, Bijlsma JWJ. Pain and disability in patients with osteoarthritis of hip or knee: the relationship with articular, kinesiological, and psychological characteristics. *J Rheumatol* 1998;25:125–33.
- 61 Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ* 2003;81:646–56.
- 62 Hulme K, Safari R, Thomas S *et al.* Fatigue interventions in long term, physical health conditions: a scoping review of systematic reviews. *PLoS One* 2018;13: e0203367.
- 63 Hurley M, Dickson K, Hallett R *et al.* Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review. *Cochrane Database Syst Rev* 2018;4:CD010842.
- 64 O'moore KA, Newby JM, Andrews G *et al.* Internet cognitive-behavioral therapy for depression in older adults with knee osteoarthritis: a randomized controlled trial. *Arthritis Care Res* 2018;70:61–70.
- 65 Breedveld FC. Osteoarthritis—the impact of a serious disease. *Rheumatology* 2004;43:i4–8.
- 66 Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. *BMC Musculoskelet Disord* 2008;9:116.
- 67 Szebenyi B, Hollander AP, Dieppe P *et al.* Associations between pain, function, and radiographic features in osteoarthritis of the knee. *Arthritis Rheum* 2006;54: 230–5.
- 68 Dell'Isola A, Allan R, Smith SL, Marreiros SSP, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. *BMC Musculoskelet Disord* 2016;17:425.
- 69 Deveza LA, Loeser RF. Is osteoarthritis one disease or a collection of many? *Rheumatology* 2018;57(Suppl 4): iv34–42.
- 70 Nikolaus S, Bode C, Taal E, van de Laar MA. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. *Arthritis Care Res* 2013;65: 1128–46.
- 71 Correa-Rodríguez M, El Mansouri-Yachou J, Casas-Barragán A *et al.* The association of body mass index and body composition with pain, disease activity, fatigue, sleep and anxiety in women with fibromyalgia. *Nutrients* 2019;11:1193.
- 72 Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. *Rheumatology* 2019;58:v29–v#34.
- 73 Deane KD, Demoruelle MK, Kelmenson LB *et al.* Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2017;31:3–18.
- 74 Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. *Clinical Immunology* 2013;146:185–96.
- 75 Malliaras P, Cook J, Purdam C, Rio E. Patellar tendinopathy: clinical diagnosis, load management, and advice for challenging case presentations. *J Orthop Sport Phys Ther* 2015;45:887–98.
- 76 Thorpe CT, Riley GP, Birch HL, Clegg PD, Screen HRC. Fascicles and the interfascicular matrix show decreased fatigue life with ageing in energy storing tendons. *Acta Biomater* 2017;56:58–64.
- 77 Neu D, Mairesse O, Montana X *et al.* Dimensions of pure chronic fatigue: psychophysical, cognitive and biological correlates in the chronic fatigue syndrome. *Eur J Appl Physiol* 2014;114:1841–51.
- 78 Lasselín J, Layé S, Dexpert S *et al.* Fatigue symptoms relate to systemic inflammation in patients with type 2 diabetes. *Brain Behav Immun* 2012;26: 1211–9.
- 79 Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. *Int J Clin Exp Med* 2009;2:1–16.
- 80 Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional

- Questionnaire (BRAFF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAFF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). *Arthritis Care Res* 2011;63(Suppl 11):S263–86.
- 81 Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. *J Rheumatol* 2004;31:1896–902.
- 82 Donovan KA, Stein KD, Lee M *et al.* Systematic review of the Multidimensional Fatigue Symptom Inventory-Short Form. *Support Care Cancer* 2015;23:191–212.
- 83 Santos EJJ, Duarte C, Da Silva JAP, Ferreira RJO. The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. *Rheumatology* 2019; 58(Suppl 5):v3–9.
- 84 Guyatt GH, Oxman AD, Vist GE *et al.*; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
- 85 Zengarini E, Ruggiero C, Pérez-Zepeda MU *et al.* Fatigue: relevance and implications in the aging population. *Exp Gerontol* 2015;70:78–83.